Infinity Pharmaceuticals (INFI) Posts Wide Q4 Miss
Tweet
Share
E-mailGet Alerts INFI Hot Sheet
Join SI Premium – FREE
Infinity Pharmaceuticals (NASDAQ: INFI) reported Q4 EPS of ($0.53), $0.14 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $13.8 million versus the consensus estimate of $16.96 million.
Sees FY11 net cash burn of $30-$40M, net cash balance at end of year of $60-$70M.
Sees FY11 net cash burn of $30-$40M, net cash balance at end of year of $60-$70M.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
- York Space Systems, Inc. (YSS) Reports Q2 Loss of $0.31 ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
